Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms A 319 |
Target |
Mechanism CD19 modulators(B-lymphocyte antigen CD19 modulators), CD3 modulators(T cell surface glycoprotein CD3 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Systemic Lupus Erythematosus | Phase 1 | CN | 20 Jul 2024 | |
Leukemia | Phase 1 | CN | 22 Aug 2022 | |
Lymphoma | Phase 1 | CN | 22 Aug 2022 | |
Pre B-cell acute lymphoblastic leukemia | Phase 1 | CN | 07 Jun 2021 | |
B-cell lymphoma recurrent | Phase 1 | - | 15 Sep 2019 | |
B-cell lymphoma refractory | Phase 1 | - | 15 Sep 2019 | |
B-Cell Lymphoma | Phase 1 | CN | 10 Sep 2019 | |
B-Cell Leukemia | IND Application | CN | 08 Sep 2017 |
NCT06400537 (ACR2024) Manual | Phase 1 | 6 | nhvxwcwwag(scddtqhajt) = All patients had grade I-II fever (drug-related) during the treatment. No other drug-related adverse events were observed. ncdhoucijd (infpmqupdu ) View more | Positive | 24 Oct 2024 |